ATLATL and Takeda Enter MoU to Collaborate on Early-Stage Drug Development and Innovation
ATLATL, an innovation incubator and global life science research and development (R&D) platform, has signed...
Alteogen Secures Exclusive Licensing Deal with Daiichi Sankyo for Subcutaneous Enhertu
Alteogen Inc. (KOSDAQ: 196170), a South Korea-based biotechnology company, has announced an exclusive licensing agreement...
Baheal Pharmaceutical Group Leads USD 78 Million Investment in ZAP Surgical Systems
Baheal Pharmaceutical Group (SHE: 301015), a leading health services and distribution company based in China,...
AstraZeneca’s Tezspire Meets Phase III Co-Primary Endpoints in CRSwNP Study
AstraZeneca Inc., (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced positive high-level results...
Sino Medical Sciences Technology Secures Marketing Approval in Peru for HT Supreme Stent System
Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical technology company, has announced...
Jiangsu Kanion Pharmaceutical Gets FDA Approval to Test KYS202004A for Psoriasis
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a Chinese pharmaceutical company, has announced that it...
J&J Submits Regulatory Filings for Darzalex Faspro and Subcutaneous Daratumumab
Johnson & Johnson (J&J, NYSE: JNJ) has announced the submission of regulatory filings for its...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Clearance for Multiple Clinical Trials of Oncology Drugs
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a Chinese pharmaceutical company, has announced that it...
Alphamab Oncology Presents JSKN033 Phase I/II Study Results at SITC 2024
Alphamab Oncology (HKG: 9966), a China-based biopharmaceutical company, has announced the presentation of the latest...
Sino Biopharmaceutical Ltd Receives NMPA Approval for KRAS G12C Inhibitor Garsorasib
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has announced that it...
Daiichi Sankyo and Alteogen Sign $300 Million Deal to Develop Subcutaneous Enhertu
Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has entered into a potentially $300...
Dizal Pharmaceutical Submits NDA to FDA for Sunvozertinib as NSCLC Therapy
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a Chinese pharmaceutical company, has announced the submission of...
MGI Tech Co., Ltd Partners with Human Cell Atlas Consortium to Advance Cell Mapping
China-based gene sequencing specialist, MGI Tech Co., Ltd, (SHA: 688114) has announced a commercial collaboration...
AstraZeneca Confirms Executive Vice President Leon Wang’s Detention in China
AstraZeneca Inc., (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has provided an update to...
Jiangsu Kanion Pharmaceutical to Acquire Xintrum Pharmaceuticals for RMB 270 Million
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a China-based pharmaceutical company, has announced its intention...
Ascletis Pharma’s ASC47 Showcases Promising Weight Loss Results in Phase I Clinical Trial
Ascletis Pharma Inc. (HKG: 1672), a China-based pharmaceutical company, has announced positive results from a...
Nuwacell Biotechnologies Secures RMB150 Million in Series B Financing for iPSC Therapies
Nuwacell Biotechnologies Co., Ltd., a specialist in induced pluripotent stem cell (iPSC) technology based in...
Shanghai Henlius Biotech Partners with SVAX to Boost MENAT Region’s Access to Biological Drugs
Shanghai Henlius Biotech Inc. (HKG: 2696), a leading Chinese biotech company, has entered into a...
Johnson & Johnson MedTech’s Varipulse Platform Receives FDA Approval for Atrial Fibrillation Treatment
Johnson & Johnson MedTech (J&J, NYSE: JNJ) has announced that it has received marketing approval...